- Home
- GRAF vs PGEN Comparison
GRAF vs PGEN Comparison
Compare GRAF & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRAF
- PGEN
- Stock Information
- Founded
- GRAF 2021
- PGEN 1998
- Country
- GRAF United States
- PGEN United States
- Employees
- GRAF N/A
- PGEN N/A
- Industry
- GRAF
- PGEN Biotechnology: Pharmaceutical Preparations
- Sector
- GRAF
- PGEN Health Care
- Exchange
- GRAF NYSE
- PGEN Nasdaq
- Market Cap
- GRAF 288.9M
- PGEN 292.6M
- IPO Year
- GRAF 2024
- PGEN N/A
- Fundamental
- Price
- GRAF $10.08
- PGEN $0.68
- Analyst Decision
- GRAF
- PGEN Buy
- Analyst Count
- GRAF 0
- PGEN 5
- Target Price
- GRAF N/A
- PGEN $7.00
- AVG Volume (30 Days)
- GRAF 44.6K
- PGEN 929.1K
- Earning Date
- GRAF 01-01-0001
- PGEN 11-14-2024
- Dividend Yield
- GRAF N/A
- PGEN N/A
- EPS Growth
- GRAF N/A
- PGEN N/A
- EPS
- GRAF 0.25
- PGEN N/A
- Revenue
- GRAF N/A
- PGEN $3,963,000.00
- Revenue This Year
- GRAF N/A
- PGEN N/A
- Revenue Next Year
- GRAF N/A
- PGEN $426.76
- P/E Ratio
- GRAF $40.63
- PGEN N/A
- Revenue Growth
- GRAF N/A
- PGEN N/A
- 52 Week Low
- GRAF $9.03
- PGEN $0.67
- 52 Week High
- GRAF $11.02
- PGEN $1.93
- Technical
- Relative Strength Index (RSI)
- GRAF N/A
- PGEN 31.82
- Support Level
- GRAF N/A
- PGEN $0.76
- Resistance Level
- GRAF N/A
- PGEN $0.83
- Average True Range (ATR)
- GRAF 0.00
- PGEN 0.06
- MACD
- GRAF 0.00
- PGEN -0.02
- Stochastic Oscillator
- GRAF 0.00
- PGEN 1.83
About GRAF GRAF GLOBAL CORP
Graf Global Corp is a blank check company.
About PGEN Precigen Inc.
Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.